PsyBio

PsyBio Therapeutics is focused on drug discovery and development. They are developing novel psychoactive compounds as potential therapeutic agents for mental and neurological disorders.

PsyBio

PsyBio is working in partnership with Miami University to biologically synthesize psilocybin and compounds from other psychoactive fungi and plants.

At present, they have a patent pending for a bacterial biosynthesis technique to be used for tryptamine production. Their portfolio consists of over 80 tryptamine-derived psychoactive molecules. Additionally, PsyBio has contracted manufacturing companies Curia Global, Biose Industrie and Berkeley Labs for process development and commercialization of lead compounds.

PsyBio Therapeutics has raised $15,800,000 prior to going public in July 2021.

“Pioneering The Next Generation of Targeted Psychoactive Medications”